On August 31, 2011, Xu, Kefu published a patent.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Synergistic pharmaceutical composition for treating swine streptococcosis and preparation method thereof. And the patent contained the following:
Title pharmaceutical composition is prepared from (by%) amoxicillin 3-10, sulfadiazine sodium 5-15, trimethoprim (TMP) lactate 1-3, sodium carbonate 5, sodium bicarbonate 5-15, paracetamol 5-15, and anhydrous glucose in balance, by mixing for 1 h. In the composition, amoxicillin and sulfadiazine sodium are anti-pathogen constituents, can improve susceptibility of pathogen and reduce probability of drug resistance, and are effective to secondary bacterial infection; TMP lactate has remarkable synergism for amoxicillin and sulfadiazine sodium; sodium carbonate acts as cosolvent; sodium bicarbonate can reduce side effect of sulfadiazine sodium and prevent generation of crystalluria; and paracetamol has fast antifebrile and antiinflammatory effects. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate
The Article related to synergistic pharmaceutical composition swine streptococcosis veterinary preparation, amoxicillin sulfadiazine sodium trimethoprim lactate paracetamol, Pharmacology: Effects Of Antimicrobials and Parasiticides and other aspects.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia